京新藥業(002020.SZ):全資子公司恩諾沙星原料藥獲得歐洲CEP證書
格隆匯6月23日丨京新藥業(002020.SZ)公佈,近日,公司全資子公司紹興京新藥業有限公司(以下簡稱"紹興京新")收到歐洲藥品質量管理局(以下簡稱"EDQM")簽發的原料藥歐洲藥典適用性證書(以下簡稱"CEP證書")。
恩諾沙星屬於喹諾酮類化學合成抑菌劑,主要用於治療動物的感染性疾病。對支原體、大腸桿菌、克雷白桿菌、沙門氏菌、變形桿菌、綠膿桿菌等都有殺滅效用。紹興京新於2023年4月向EDQM提交恩諾沙星原料藥CEP申請,於2024年6月21日獲得批准。
根據Pharmarket數據查詢,恩諾沙星原料藥2023度全球使用量約3910噸,其中歐盟市場用量約425噸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.